Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H22N6O7S2 · 5H2O
CAS Number:
Molecular Weight:
636.65
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
ceftazidime
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
SMILES string
[s]1c(nc(c1)\C(=N\OC(C)(C)C(=O)[O-])\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)[O-])C[n+]4ccccc4)N.O.O.O.O.O.[H+]
InChI
1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1
InChI key
NMVPEQXCMGEDNH-TZVUEUGBSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ceftazidime pentahydrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Ceftazidime
- Ceftazidime Injection
- Ceftazidime for Injection
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
signalword
Danger
hcodes
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ceftazidime
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 45(3), 872-872 (2018)
S Segal-Maurer et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28(5), 1134-1138 (1999-08-19)
Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt-associated ventriculitis due to ceftazidime-resistant Klebsiella
Kai Ming Chow et al.
Pharmacotherapy, 23(3), 369-373 (2003-03-12)
We reviewed 42 cases of cefepime-induced neurotoxicity and 12 cases of ceftazidime-induced neurotoxicity from the literature and our institution. Clinical characteristics and timing of diagnosis were examined. Common findings were confusion with temporospatial disorientation (96% of patients), myoclonus (33%), and